Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 14/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 14/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 14/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24908472 | 0.81 | OGA (0.43) | — | |
| SCHEMBL2609437 | 0.78 | MAPKAPK2 (0.48) | ALDH1A1SMN1; SMN2IDH1 | |
| SCHEMBL24921475 | 0.77 | TDO2 (0.37) | RXRAGRIN1GRIN2BALDH1A1 | |
| SCHEMBL2611025 | 0.75 | ALDH1A1 (0.40) | RXRAGRIN1GRIN2BALDH1A1SMN1; SMN2 | |
| SCHEMBL14328380 | 0.74 | NOTUM (0.48) | RXRAGRIN1GRIN2BIDH1 | |
| SCHEMBL14207203 | 0.74 | HSP90AA1 (0.41) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL22902068 | 0.74 | NOTUM (0.50) | ALDH1A1EGLN1 | |
| SCHEMBL20575433 | 0.73 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL12351974 | 0.73 | GAA (0.53) | SMN1; SMN2IDH1 | |
| SCHEMBL26051361 | 0.71 | MAPT (0.42) | RXRAGRIN1GRIN2BALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014445-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014445-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | RXRA 1049/4885GRIN1 2596/4885GRIN2B 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.